Donaldson Capital Management LLC Acquires Shares of 2,736 AstraZeneca PLC $AZN

Donaldson Capital Management LLC purchased a new stake in AstraZeneca PLC (NASDAQ:AZN) in the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund purchased 2,736 shares of the company’s stock, valued at approximately $210,000.

Several other institutional investors have also recently bought and sold shares of AZN. NewSquare Capital LLC raised its holdings in AstraZeneca by 149.3% during the 2nd quarter. NewSquare Capital LLC now owns 364 shares of the company’s stock worth $25,000 after purchasing an additional 218 shares during the last quarter. Richardson Financial Services Inc. grew its stake in AstraZeneca by 59.8% in the second quarter. Richardson Financial Services Inc. now owns 398 shares of the company’s stock valued at $28,000 after acquiring an additional 149 shares during the period. Rakuten Investment Management Inc. acquired a new position in shares of AstraZeneca in the third quarter valued at approximately $31,000. FSA Wealth Management LLC raised its position in AstraZeneca by 376.0% in the 2nd quarter. FSA Wealth Management LLC now owns 476 shares of the company’s stock valued at $33,000 after buying an additional 376 shares during the last quarter. Finally, VSM Wealth Advisory LLC bought a new position in AstraZeneca in the second quarter valued at $33,000. Institutional investors own 20.35% of the company’s stock.

AstraZeneca Stock Up 105.8%

AZN stock opened at $190.57 on Monday. The company has a current ratio of 0.88, a quick ratio of 0.69 and a debt-to-equity ratio of 0.54. The stock has a market cap of $591.11 billion, a P/E ratio of 63.31, a P/E/G ratio of 1.59 and a beta of 0.34. AstraZeneca PLC has a 1-year low of $61.24 and a 1-year high of $96.51. The stock’s fifty day simple moving average is $92.29 and its two-hundred day simple moving average is $84.48.

AstraZeneca (NASDAQ:AZN) last posted its quarterly earnings results on Thursday, November 6th. The company reported $1.19 EPS for the quarter, topping analysts’ consensus estimates of $1.14 by $0.05. AstraZeneca had a net margin of 16.17% and a return on equity of 32.89%. The company had revenue of $15.19 billion for the quarter, compared to analysts’ expectations of $14.75 billion. During the same quarter in the previous year, the firm posted $2.08 EPS. AstraZeneca’s revenue was up 12.0% on a year-over-year basis. Analysts expect that AstraZeneca PLC will post 4.51 EPS for the current year.

Wall Street Analysts Forecast Growth

AZN has been the subject of a number of recent analyst reports. Jefferies Financial Group began coverage on shares of AstraZeneca in a research report on Monday, October 27th. They issued a “buy” rating for the company. TD Cowen reissued a “buy” rating on shares of AstraZeneca in a research note on Tuesday, December 9th. Citigroup initiated coverage on shares of AstraZeneca in a report on Tuesday, January 27th. They set a “buy” rating for the company. Deutsche Bank Aktiengesellschaft reiterated a “sell” rating on shares of AstraZeneca in a report on Friday, January 16th. Finally, Weiss Ratings restated a “buy (b)” rating on shares of AstraZeneca in a report on Wednesday, January 21st. Ten research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $95.75.

AstraZeneca Profile

AstraZeneca is a global, science-led biopharmaceutical company headquartered in Cambridge, England. Formed through the 1999 merger of Sweden’s Astra AB and the UK’s Zeneca Group, the company researches, develops, manufactures and commercializes prescription medicines across a range of therapeutic areas. AstraZeneca’s operations span research and development, large-scale manufacturing, and commercial distribution, with a presence in developed and emerging markets worldwide.

The company focuses on several core therapy areas including oncology, cardiovascular, renal and metabolism (CVRM), respiratory and immunology, and rare diseases.